incobotulinumtoxinA

Known as: BoNT-A 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
0102020052018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Botulinum toxin (BT) used for dystonia and spasticity is dosed according to the number of target muscles and the severity of… (More)
  • table 1
  • figure 1
  • table 2
Is this relevant?
2013
2013
IncobotulinumtoxinA (Xeomin®, NT 201) is a purified botulinum toxin type A free from accessory (complexing) proteins. Previous… (More)
  • table 2
  • table 1
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2013
2013
Several botulinum toxin (BT) drugs are licensed for the treatment of cervical dystonia (CD). We wanted to compare the efficacy… (More)
  • figure 1
Is this relevant?
2013
2013
INTRODUCTION Previously, controlled trials have demonstrated the efficacy and tolerability of fixed doses of incobotulinumtoxinA… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2011
2011
OBJECTIVE IncobotulinumtoxinA differs from available formulations in that it does not have accessory proteins… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2011
2011
The biological potency of botulinum toxin (BT) drugs is determined by a standardised LD50 assay. However, the potency labelling… (More)
  • table 1
  • table 2
Is this relevant?
2011
2011
OBJECTIVE To investigate the efficacy and safety of incobotulinumtoxinA (also known as botulinum toxin type A [150 kDa], free… (More)
Is this relevant?
2011
2011
IncobotulinumtoxinA (NT 201, Xeomin) is a highly purified botulinum neurotoxin type A formulation, free from complexing proteins… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2011
2011
Even though conventional botulinum neurotoxin (BoNT) products have shown successful treatment results in patients with benign… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2010
2010
BACKGROUND Use of botulinum toxin for esthetic purposes has rapidly expanded over the last 20 years. IncobotulinumtoxinA, also… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?